AzTrials
AzTrials

Morbid ObesityNCT03913858

Low Flow Anesthesia in Morbid Obesity

A study testing Obesity Surgery with Low-Flow Anesthesia and Obesity Surgery with High-Flow Anesthesia in people with Morbid Obesity and Anesthesia Complication, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study to planned to research the efficacy of low-flow anesthesia on patients undergoing sleeve gastrectomy due to morbid obesity on respiratory functions after surgery by examining FEV1 and FVC values and FEV1/FVC ratio. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Obesity Surgery with Low-Flow Anesthesia and Obesity Surgery with High-Flow Anesthesia
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteTurkey (Türkiye)
Study dates
10 Jan 2019to 10 Apr 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • american Society of Anesthesiologists (ASA) III
  • body mass index (BMI) >40.
  • FEV1/FVC ratio within normal limits
  • FEV1 and FVC values within normal limits
  • those with stop-bang score below 4

Who cannot join

  • alcohol abuse
  • drug abuse
  • previous abdominal surgery.
  • chronic obstructive pulmonary disease (COPD)

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Bakırköy Dr. Sadi Konuk Trainig And Research Hospital

    Istanbul

Other trials in Turkey (Türkiye)

About this study

Official title: Does Low Flow Anesthesia Protect Lung Functions in Laparoscopic Sleeve Gastrectomy?

In this study to planned to research the efficacy of low-flow anesthesia on patients undergoing sleeve gastrectomy due to morbid obesity on respiratory functions after surgery by examining FEV1 and FVC values and FEV1/FVC ratio.

Read the detailed description

Morbid obese patients undergoing sleeve gastrectomy due to morbid obesity after 01.01.2019 will be randomly divided into 2 groups with controls. To prevent selection bias in the study, numbers will be produced at random. The produced numbers will be determined as 0: control and 1: experiment groups and patients will be divided into groups as such. Random numbers will be generated by the MedCalc 18.2.1. program (MedCalc Statistical Software MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018). Group 1 is determined as patients to be administered high-flow anesthesia, while Group 2 will be administered low-flow anesthesia. After anesthesia induction, Group 1 will have 4 liters/minute (50% O2 50%) flow administered, while patients in Group 2 will have 1 liter/minute (50% O2, 50% air) flow administered. The study included adult patients who signed the voluntary consent form aged from 18-65 years, American Society of Anesthesiologists (ASA) III, and body mass index (BMI) >40. Inclusion criteria for the study are no alcohol or drug addiction or diagnosis of chronic obstructive pulmonary disease (COPD) during routine preoperative assessment by chest diseases, FEV1/FVC ratio, FEV1 and FVC values within normal limits and no previous abdominal surgery.

Those with stop-bang score below 4 will be included in the study. On the day of surgery, all patients had FEV1, FVC value and FEV1/FVC ratio examined by a single anesthesia technician using a manual RST device without the knowledge of the anesthesia expert.

Pressure tests and calibration of the anesthesia device is performed each morning for every surgery. After calibration the mechanical ventilator alarm limits for ins O2 are lower limit 40%, EtCO2 35-45 mmHg, min Vol (tidal volume in 1 min x frequency) according to the patient ± 0.5. After patient is placed on the operating table in ramp position, all patients are monitored with triple route ECG, pulse oximetry and pressure cuff. The clinical protocol for all patients undergoing sleeve gastrectomy includes BIS (bispectral index) and TOF (train of four) monitoring. Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. Patients were ventilated with 6 L/min 60% O2 for 2 minutes. Patients were endotracheally intubated with a Macintosh laryngoscope. In addition to assessment of respiratory sounds linked to obesity with auscultation, EtCO2 capnography was used to confirm the efficacy of intubation. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Sevoflurane percentage was changed to ensure MAC (minimum alveolar concentration of 0.6-1.1 for BIS score of 40-60 for maintenance. During ventilation in PRVC mode, Group 1 had 4 liter/minute (50% O2, 50% air) flow administered, while Group 2 had 3 L/min 4% for Sevoflurane the first 3 minutes as wash-in. Then flow was administered at 1 L/min (50% O2, 50% air). According to ideal weight, mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. In Group 1, sevoflurane percentage was set to correlate with BIS monitoring. In Group 2, after intubation the sevoflurane percentage was set to a higher percentage to reach the desired MAC value. Every 5 minutes during surgery, MAC, BIS, mean arterial pressure, peak heart rate, sPO2, etCO2, inSO2, frequency and PEEP values were recorded. In Group 2, 5 minutes before the end of surgery, flow was increased from 1 L to 4 L for wash-out. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered. Five minutes before the end of the operation patient-controlled SIMV+VE mode with trigger setting of 6 was organized. At the end of surgery, patients were administered 2 mg/kg sugammadex according to ideal weight. When the patients trigger setting reaches muscle power it was lowered to zero. When trigger is zero and there is sufficient tidal volume to reach TOF (train of four) value >90% and BIS score is 80-100, patients were extubated. They were sent to the recovery room. In recovery the ARISCAT risk index was calculated. Later when modified Aldrete scoring system is ≥9, patients were sent to the ward.

After surgery, mobilization and respiratory physiotherapy were provided in the 2nd hour. Vital signs including mean arterial pressure (MAP) were recorded in the postoperative period with 20 mg tenoxicam I.V. administered in the 1st hour. The PCA device was set with tramadol 300 mg/100 ml, bolus 10 mg, lock time 12 minutes without basal infusion. Patients with numeric rating scale (NRS) scores ≥4 had a rescue dose of 4 mg morphine I.V. administered. Each patient began oral intake (water) in the postoperative 24th hour, with early mobilization. A second dose of tenoxicam I.V. was administered in the postoperative 8th hour.

In the 24th hour postoperative, patients had analgesia to ensure VAS score is below 4, with RFT repeated by the same doctor who performed RFT preoperatively.

Being tested
Obesity Surgery with Low-Flow Anesthesia, Obesity Surgery with High-Flow Anesthesia
Keywords
Morbid Obesity, Sleeve Gastrectomy, Low Flow Anesthesia
Medical subject headings
Obesity, Morbid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Obesity Surgery with Low-Flow AnesthesiaProcedure or surgery

    Also called Procedure/Anesthesia

    Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.

  • Obesity Surgery with High-Flow AnesthesiaProcedure or surgery

    Also called Procedure/Anesthesia

    Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.

Study groups in NCT03913858
Study groupRoleWhat they receive
high-flow anesthesiaOtherBefore beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
Receives: Procedure: Obesity Surgery with High-Flow Anesthesia
low-flow anesthesiaOtherBefore beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
Receives: Procedure: Obesity Surgery with Low-Flow Anesthesia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pulmonary Function Test Results

    FEV1/FVC (%) ratio in hundred morbid obese patients who will undergo laparoscopic sleeve gastrectomy under low flow and high flow anesthesia will be measured

    Measured: Preoperative 1st hour and postoperative 24th hours

Secondary outcomes (1)
  1. Length of hospital stay

    Length of hospital stay (days) of hundred morbid obese patients who will undergo laparoscopic sleeve gastrectomy under low flow and high flow anesthesia will be measured.

    Measured: Up to 72th hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2019
  2. Study start10 Jan 2019
  3. Primary completion10 Mar 2020
  4. Study completion10 Apr 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03913858
Sponsor's protocol ID
Obesity Surgery FEV1/FVC
Other IDs
Evrim Kucur Tulubas
Status last verified
Jul 2020
First submitted
21 Feb 2019
Last updated
13 Jul 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Obesity Surgery with Low-Flow Anesthesia and Obesity Surgery with High-Flow Anesthesia in people with Morbid Obesity and Anesthesia Complication, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pulmonary Function Test Results (time frame: Preoperative 1st hour and postoperative 24th hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in